Guardant360 (GH) Forward P/S Multiple

Guardant Health, Inc. (GH) delegates clinical testing and sample transportation to external partners, creating a certain dependency on contractors. The company is implementing innovative liquid biopsy, displacing traditional cancer diagnostic methods. Outsourcing computation optimization and sequencer assembly accelerates the delivery of results. The future P/S ratio demonstrates the boundaries of trading ranges, where the current status equals 16.30.

GH (guardanthealth.com) Forward P/S Multiple history from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Guardant Corp (GH)

- market price and analyst price targets:

Price Chart Guardant Health|GH - Analyst Median Target

- market capitalization details:

Market Capitalization Guardant Corp|GH - Full Takeover Company Value

- issuer book value statistics:

Accounting Value per Share Guardant Health|GH - Book Capitalization|Market Capitalization to Book Value Ratio guardanthealth.com|GH - Company Total Assets

- debt and liquidity details:

- net income and valuation multiples indicators:

GH - Profit After Payment of Taxes|Future Profit Guardant Health, Inc.|GH - Company Value to Net Income|Forward P/E Multiple Guardant360|GH - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Guardant Corp|GH - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Guardant Health|GH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months guardanthealth.com|GH - Earnings per share growth in current year|Expected earnings per share growth for next year Guardant Health, Inc.

- total revenue and sales volume data:

GH - Company Total Sales|Projected Sales Volume Guardant Health|GH - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Guardant Corp

Fundamental company valuation:Guardant Health GH

The forward P/S ratio reflects the market value of assets through the lens of discounted future cash flows, allowing investors to assess the premium paid for expected revenue growth. When analyzing the projected P/S valuation, it is essential to note that the metric's dynamics for Guardant Health, Inc. (GH) depend directly on the scaling of liquid biopsy sales and the demand for high-tech oncology tests within targeted therapy and pharmaceuticals.

Competitors of Guardant Health, Inc.

Price-to-Projected Revenue Ratio Caris Life Sciences CAI|Market Cap to Expected Sales Ratio Veracyte Inc (VCYT)|Celcuity Corp - Forward P/S Multiple|Projected Price to Revenue GRAIL Bio (GRAL)|MYGN (Myriad Genetics, Inc.) - Forward Price-to-Revenue Multiple|castlebiosciences.com (CSTL) - Forward P/S Multiple|BNR (Burning Rock) - Forward P/S Multiple|Forward P/S Multiple VolitionRx Ltd|Price-to-Projected Revenue Ratio Biodesix Corp (BDSX)|PRPO (Precipio Inc) - Forward Price to Sales|Forward P/S Multiple CHEK (Check-Cap)|MYNZ: Market Cap to Projected Revenue|OncoCyte - Forward P/S Multiple